US brain health company Sage Therapeutics (Nasdaq: SAGE) was trading more than 19% lower at lunchtime Wednesday.
The company earlier announced top-line results from PRECEDENT, a double-blind, placebo-controlled Phase II study of the investigational oral medicine dalzanemdor (SAGE-718) in people with mild cognitive impairment in Parkinson’s disease.
PRECEDENT did not meet its primary endpoint of demonstrating statistically-significant difference from baseline in participants treated on a measure of cognitive ability in adults at day 42.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze